NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free WGS Stock Alerts $19.61 -0.78 (-3.83%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$19.54▼$21.3250-Day Range$8.48▼$24.0252-Week Range$1.16▼$24.40Volume323,885 shsAverage Volume496,793 shsMarket Capitalization$512.21 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GeneDx alerts: Email Address GeneDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside8.2% Downside$18.00 Price TargetShort InterestBearish7.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.20Based on 11 Articles This WeekInsider TradingAcquiring Shares$2.04 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.02) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.22 out of 5 starsMedical Sector780th out of 928 stocksHealth Services Industry8th out of 10 stocks 1.3 Analyst's Opinion Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.16% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently increased by 0.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WGS. Previous Next 3.4 News and Social Media Coverage News SentimentGeneDx has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for GeneDx this week, compared to 1 article on an average week.Search Interest12 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 792.97% more of their company's stock than they have sold. Specifically, they have bought $2,039,270.00 in company stock and sold $228,370.00 in company stock.Percentage Held by Insiders28.10% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($2.02) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About GeneDx Stock (NASDAQ:WGS)GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More WGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WGS Stock News HeadlinesMay 29, 2024 | insidertrades.comInsider Buying: GeneDx Holdings Corp. (NASDAQ:WGS) Director Purchases 7,500 Shares of StockMay 16, 2024 | insidertrades.comCasdin Capital, Llc Acquires 50,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockMay 30 at 5:48 AM | americanbankingnews.comCasdin Capital, Llc Purchases 7,500 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockMay 30 at 1:36 AM | americanbankingnews.comGeneDx (NASDAQ:WGS) Shares Gap Up After Insider Buying ActivityMay 29, 2024 | msn.comOver $4M Bet On ProFrac Holding? Check Out These 3 Stocks Insiders Are BuyingMay 29, 2024 | americanbankingnews.comGeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc Acquires 18,304 Shares of StockMay 22, 2024 | globenewswire.comGeneDx to Participate in Upcoming Investor ConferencesMay 2, 2024 | finance.yahoo.comGeneDx Holdings Corp. (NASDAQ:WGS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesApril 30, 2024 | finanznachrichten.deGeneDx Holdings Corp.: GeneDx Reports First Quarter 2024 Financial Results and Business HighlightsApril 30, 2024 | markets.businessinsider.comGeneDx is about to announce its earnings — here's what to expectApril 30, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues and ...April 29, 2024 | msn.comWGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024April 29, 2024 | msn.comGeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 GuidanceApril 29, 2024 | finance.yahoo.comGeneDx Holdings Corp (WGS) Q1 2024 Earnings: Surpasses Revenue Expectations and Narrows LossesApril 29, 2024 | msn.comGeneDx reports Q1 resultsApril 29, 2024 | globenewswire.comGeneDx Reports First Quarter 2024 Financial Results and Business HighlightsApril 28, 2024 | msn.comGeneDx Q1 2024 Earnings PreviewApril 27, 2024 | finance.yahoo.comGeneDx Holdings Corp. (WGS)April 23, 2024 | finance.yahoo.comGeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease DatasetApril 23, 2024 | globenewswire.comGeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease DatasetApril 4, 2024 | globenewswire.comGeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024March 16, 2024 | finance.yahoo.comWGS Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comWGS Apr 2024 7.500 putMarch 14, 2024 | globenewswire.comGeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of GenomicsMarch 13, 2024 | edition.cnn.comGeneDx Holdings Corp. Class ASee More Headlines Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today6/01/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:WGS CUSIPN/A CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$24.00 Low Stock Price Target$11.00 Potential Upside/Downside-8.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-60.86% Pretax Margin-61.25% Return on Equity-36.23% Return on Assets-20.92% Debt Debt-to-Equity Ratio0.25 Current Ratio3.22 Quick Ratio2.99 Sales & Book Value Annual Sales$202.57 million Price / Sales2.53 Cash FlowN/A Price / Cash FlowN/A Book Value$7.93 per share Price / Book2.47Miscellaneous Outstanding Shares26,120,000Free Float18,782,000Market Cap$512.21 million OptionableOptionable Beta2.17 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Katherine A. Stueland (Age 48)President, CEO & Director Comp: $745.91kMr. Kevin Feeley (Age 43)Chief Financial Officer Comp: $488.19kMs. Karen PonchnerSenior VP & Head of OperationsMr. Eric Olivares Ph.D.Chief Product & Technology OfficerMr. Devin K. Schaffer J.D.M.B.A., General CounselMr. Paul Kruszka M.D.Chief Medical OfficerMs. Melanie DuquetteChief Growth OfficerSabrina DunbarChief of StaffMore ExecutivesKey CompetitorsLifeStance Health GroupNASDAQ:LFSTPrivia Health GroupNASDAQ:PRVAU.S. Physical TherapyNYSE:USPHThe Pennant GroupNASDAQ:PNTGInnovAgeNASDAQ:INNVView All CompetitorsInsiders & InstitutionsCasdin Capital, LlcBought 18,304 shares on 5/28/2024Total: $377,245.44 ($20.61/share)Casdin Capital, LlcBought 7,500 shares on 5/23/2024Total: $146,925.00 ($19.59/share)Jacobs Levy Equity Management Inc.Sold 111,596 shares on 5/16/2024Ownership: 0.774%Oracle Investment Management Inc.Bought 948,253 shares on 5/15/2024Ownership: 4.313%Gagnon Securities LLCBought 207,027 shares on 5/14/2024Ownership: 2.130%View All Insider TransactionsView All Institutional Transactions WGS Stock Analysis - Frequently Asked Questions Should I buy or sell GeneDx stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WGS shares. View WGS analyst ratings or view top-rated stocks. What is GeneDx's stock price target for 2024? 3 Wall Street analysts have issued 1-year target prices for GeneDx's stock. Their WGS share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests that the stock has a possible downside of 8.2%. View analysts price targets for WGS or view top-rated stocks among Wall Street analysts. How have WGS shares performed in 2024? GeneDx's stock was trading at $2.75 on January 1st, 2024. Since then, WGS shares have increased by 613.1% and is now trading at $19.61. View the best growth stocks for 2024 here. When is GeneDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our WGS earnings forecast. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) issued its quarterly earnings data on Monday, April, 29th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.35. The business had revenue of $62.42 million for the quarter, compared to the consensus estimate of $49.80 million. GeneDx had a negative trailing twelve-month return on equity of 36.23% and a negative net margin of 60.86%. When did GeneDx's stock split? Shares of GeneDx reverse split on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has GeneDx issued on next quarter's earnings? GeneDx issued an update on its FY 2024 earnings guidance on Monday, April, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $235.0 million-$245.0 million, compared to the consensus revenue estimate of $226.1 million. Who are GeneDx's major shareholders? GeneDx's stock is owned by many different retail and institutional investors. Top institutional investors include Oracle Investment Management Inc. (4.31%), Vanguard Group Inc. (2.71%), Gagnon Securities LLC (2.13%), Gagnon Advisors LLC (0.81%), Jacobs Levy Equity Management Inc. (0.77%) and Thompson Davis & CO. Inc. (0.09%). Insiders that own company stock include Anthony Prentice, Casdin Capital, Llc, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard C Pfenniger Jr, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WGS) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.